WO2022180448A1 - Porous silica globules impregnated by a denaturing mixture able to capture and dissolve airborne viruses - Google Patents
Porous silica globules impregnated by a denaturing mixture able to capture and dissolve airborne viruses Download PDFInfo
- Publication number
- WO2022180448A1 WO2022180448A1 PCT/IB2022/000048 IB2022000048W WO2022180448A1 WO 2022180448 A1 WO2022180448 A1 WO 2022180448A1 IB 2022000048 W IB2022000048 W IB 2022000048W WO 2022180448 A1 WO2022180448 A1 WO 2022180448A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- porous silica
- mixture
- globules
- cholesterol
- viral
- Prior art date
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 239000000377 silicon dioxide Substances 0.000 title claims abstract description 29
- 241000700605 Viruses Species 0.000 title claims abstract description 20
- 239000000725 suspension Substances 0.000 claims abstract description 18
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 15
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 9
- 230000007613 environmental effect Effects 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 210000000234 capsid Anatomy 0.000 claims abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 39
- 230000003612 virological effect Effects 0.000 claims description 25
- 150000002632 lipids Chemical class 0.000 claims description 23
- 235000012000 cholesterol Nutrition 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 8
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 8
- 238000005470 impregnation Methods 0.000 claims description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 8
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 6
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004160 Ammonium persulphate Substances 0.000 claims description 5
- 235000019395 ammonium persulphate Nutrition 0.000 claims description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 5
- 108070000030 Viral receptors Proteins 0.000 claims description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 4
- -1 sialic acid gangliosides Chemical class 0.000 claims description 4
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- YXJUEYDETJCBKA-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OCCNCCO YXJUEYDETJCBKA-UHFFFAOYSA-N 0.000 claims description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 3
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000004925 denaturation Methods 0.000 claims description 2
- 230000036425 denaturation Effects 0.000 claims description 2
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 claims description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000009830 intercalation Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000010534 mechanism of action Effects 0.000 claims 3
- 238000010348 incorporation Methods 0.000 claims 2
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 238000005213 imbibition Methods 0.000 claims 1
- 230000002687 intercalation Effects 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 239000012466 permeate Substances 0.000 claims 1
- 238000005502 peroxidation Methods 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000005855 radiation Effects 0.000 abstract description 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 238000005202 decontamination Methods 0.000 description 3
- 230000003588 decontaminative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010055409 ganglioside receptor Proteins 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
- A01N25/06—Aerosols
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/02—Acyclic compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
- A61L9/012—Deodorant compositions characterised by being in a special form, e.g. gels, emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
- A61L9/014—Deodorant compositions containing sorbent material, e.g. activated carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/14—Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances including air-liquid contact processes
Definitions
- Virus decontamination of solid surfaces - even large ones - is relatively simple using proven techniques such as solvents, soaps, high-temperature vapours and can be carried out in various ways.
- the pathogenic suppression of the air for considerable volumes and over time is rather problematic, especially for air treatment systems with aerosols. Although they afford maximum viral removal capacity, there is still the problem of eliminating the vapour in the equipment without releasing residues of irritating substances.
- the globules covered by this patent application are composed of a central core of amorphous silica with an average diameter " ⁇ s " of about 10 pm ( Figure 1). On the surface of these, a mantle composed of a phospholipid bilayer is deposited.
- guanidinium thiocyanate, guanidinium chloride, and sodium dodecyl sulphate are able to break disulphide bridges in viral capsid proteins, deforming their tertiary structure and allowing them to be more easily dissolved by the solvent dimethyl sulphoxide.
- Fig. 1 shows the amorphous silica core (1) with the surface cavities (2) containing the mixture in aqueous form.
- the amorphous silica core (1) is covered by the lipid mantle (3), which has lipid rafts with viral receptors for virus attachment (4).
- the mantle shown in more detail in the enlargement in Fig. 2, is formed by a lipid bilayer of phospholipids (3) with a different composition.
- the first layer adheres to the silica core (6), and the second is in contact with the external environment (5).
- the second phosphatidylcholine layer (5) contains nanogranules (4) consisting of 70% cholesterol, 18% linoleic acid C 18 H 32 O 2 , 10% sialic acid ganglioside GM1, 1.5% carnosic acid C 20 H 28 O 4 , and 0.5% tetramethylethylenediamine (TEMED) C 6 H 16 N 2 .
- nanogranules (4) consisting of 70% cholesterol, 18% linoleic acid C 18 H 32 O 2 , 10% sialic acid ganglioside GM1, 1.5% carnosic acid C 20 H 28 O 4 , and 0.5% tetramethylethylenediamine (TEMED) C 6 H 16 N 2 .
- the nanogranules (4) inserted into the second lipid layer (6) create lipid rafts that are positioned near the cavities (2) of the amorphous silica core (1).
- the nanogranules (4) that make up the lipid rafts perform the dual function of viral receptor and virus entry port (10). This is the core of the cellular mimesis function performed by the globule as shown in the sequences in Fig. 3.
- each globule of porous silica has an extraordinary capacity for surface capture. This is due to the size (i.e. that of viruses with an average diameter more than 100 times smaller). It has been calculated that each porous silica globule has the potential to capture 30,000 viral particles with an average diameter of 100 nm because each viral particle engages a surface area of approximately 0.01 pm 2 and a porous silica globule (10 pm in diameter) has a mantle area of over 300 pm 2 .
- aqueous suspension can contain approximately one billion globules of porous silica
- a bottle with a volume of 100 ml can contain as many as one hundred billion globules of porous silica with a capture potential of 3 million billion viral particles.
- the globular suspension is obtained in six sequential steps as shown in Fig. 4 and is based on the property of porous silica to absorb at temperatures around 60°C a quantity of liquid mixture of saturation approximately 25% higher than the quantity of saturation at room temperature of 20°C. During cooling, a part of the mixture is desorbed and fills the surface cavities of the porous silica because of the equilibrium of the pressure inside the globule with respect to the outside. This results in a pseudo- spherical conformation of the lipid mantle (3).
- the porous silica globules are impregnated at 60°C with the mixture (dissolving denaturing solution) for proteins and nucleic acids, thus bringing the globules to saturation.
- the first lipid mantle is created on the porous silica globules by introducing them into a mixture of phosphatidylcholine and phosphate- diethanolamine with the globules in excess of the lipids and maintaining the temperature at around 55°C so that the polar heads of the uniform phospholipids adhere around the globule until the porous surface cavities are partially filled.
- the third step (15) (Fig. 4), consists in the preparation of the nanogranules of cholesterol and sialic acid gangliosides by inserting their homogeneous mixture in a dissolver with water until a size of about 200 nm is obtained.
- the second lipid mantle formed by the phosphatidylcholine and phosphatidylserine is formed by inserting this into the globular suspension so that the mantle is uniformly coated at a temperature of 45°C.
- the phospholipids of the second layer will be arranged with the polar heads outwards and the lipid tails attached to the first mantle.
- Lipid rafts form on the outside of the lipid bilayer, and cavities are filled with dissolving denaturing mixture in the area below; magnification of the illustration (2X) (Fig. 4).
- the globules formed by this serial process are suitable for the capture and dissolution of suspended pathogens.
- a bottle of 100- 200 ml of globular suspension is sufficient to guarantee decontamination from viral pathogens for 8-10 weeks of continuous 24-hour sanitisation.
- the fluorescein isothiocyanate C 2 1H11NO5S also penetrates the cholesterol nanogranule around the viral pericapside residues and attaches to the fostatidylserine present in this, thereby creating a fluorescent halo.
- Fluorescent dyes reveal when the dispersion needs to be replaced because the globules are coloured orange when exposed to sunlight and become extremely fluorescent when subjected to UV light.
- ammonium persulphate (NH 4 ) 2 S 2 O 8 has also been added to the impregnation; the function of this is to peroxidise and polymerise the linolenic acid with the cholesterol present in the granule; this polymerisation occurs after virus capture and dissolution and is essential to prevent the cholesterol granule from being dissolved by the dimethyl sulfoxide C 2 H 6 OS present in the impregnation mixture and from crossing the phospholipid membrane and spilling outside the globular suspension.
- TEMED tetramethylethylenediamine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Porous silica globules impregnated with a denaturing mixture and provided with a phospholipid mantle placed in an aqueous suspension in order to capture and dissolve airborne viruses. The porous silica globules are impregnated with a specific denaturing mixture to break down the encapsulated protein capsids and virus nuclei. The globular suspension can be applied to all environmental sanitation systems that treat the air for pathogen abatement - also with the complementary use of UV radiation.
Description
Porous silica globules impregnated a denaturing mixture and provided with a phospholipid mantle placed in an aqueous suspension to capture and dissolve airborne viruses
DESCRIPTION
Virus decontamination of solid surfaces - even large ones - is relatively simple using proven techniques such as solvents, soaps, high-temperature vapours and can be carried out in various ways. On the other hand, the pathogenic suppression of the air for considerable volumes and over time is rather problematic, especially for air treatment systems with aerosols. Although they afford maximum viral removal capacity, there is still the problem of eliminating the vapour in the equipment without releasing residues of irritating substances.
In order to overcome the criticality of such environmental sanitation systems, a technological system that simulates cellular mimesis to facilitate the capturing and dissolution of viral particles has been developed
For the latest generation of aerosol spraying systems, in particular those using electro-sprays in combination with UV radiation, the use of the aqueous suspension of micro-globules has been verified. This does not release any trace of volatile irritant substance into the environment being treated. Optimum performance, also in terms of safety of the result, is determined by the high concentration of antiviral mixtures in the core of the globules. These are carefully sealed against the aqueous suspension by a cell-like lipid membrane.
The suspension captures viruses already in the aerosol phase and ensures condensation, precipitation, and separation from the treated air. Viral dissolution continues even when the globules are precipitated from the aerosol and collected in the reservoir to return them to the circulation.
The globules covered by this patent application are composed of a central core of amorphous silica with an average diameter "Φs" of about 10 pm (Figure 1). On the surface of these, a mantle composed of a phospholipid bilayer is deposited.
The amorphous silica core presents a diffuse porosity which is impregnated by a mixture of compounds consisting of (by weight) water H2O (40%), dimethyl sulphoxide C2H6OS (30%), guanidinium thiocyanate C2H6N4S (10%), guanidinium chloride CH6CIN3 (6%), urea CH4N2O (5%), sodium dodecyl sulphate Ci2H2sNaS04 (4%), ammonium persulphate (NH4)2S2O8 (3%), propridium iodide C27H34I2N4 (1.1%), thiazole orange C26H24N2O3S2 (0.6%), and fluorescein Isothiocyanate C21H11NO5S (0.3%). The function of the mixture components is to act as protein denaturants, nucleic acid denaturants, and fluorescent tracers of dissolved products.
In particular, the compounds guanidinium thiocyanate, guanidinium chloride, and sodium dodecyl sulphate are able to break disulphide bridges in viral capsid proteins, deforming their tertiary structure and allowing them to be more easily dissolved by the solvent dimethyl sulphoxide.
Fig. 1 shows the amorphous silica core (1) with the surface cavities (2) containing the mixture in aqueous form. The amorphous silica core (1) is covered by the lipid mantle (3), which has lipid rafts with viral receptors for virus attachment (4).
The mantle, shown in more detail in the enlargement in Fig. 2, is formed by a lipid bilayer of phospholipids (3) with a different composition. The first layer adheres to the silica core (6), and the second is in contact with the external environment (5).
The polar heads of the phospholipids in the first layer (5) of the mantle (3) are oriented towards the amorphous silica core (1), while those in the second layer (6) are oriented outwards as shown in Fig. 2.
The first layer (6) is composed of a mixture of 60% phosphatidylcholine and 40% phosphate-diethanolamine (w/w) in order to ensure high mobility and deformation capacity and adaptation of the membrane to the geometry of the amorphous silica core (1).
The second layer (5) is composed of a mixture of 95% phosphatidylcholine and 5% phosphatidylserine (w/w), making it more rigid and viscous and able to provide resistance to environmental stress from outside the globule.
The second phosphatidylcholine layer (5) contains nanogranules (4) consisting of 70% cholesterol, 18% linoleic acid C18H32O2 , 10% sialic acid ganglioside GM1, 1.5% carnosic acid C20H28O4 , and 0.5% tetramethylethylenediamine (TEMED) C6H16N2 .
The nanogranules (4) inserted into the second lipid layer (6) create lipid rafts that are positioned near the cavities (2) of the amorphous silica core (1).
The nanogranules (4) that make up the lipid rafts perform the dual function of viral receptor and virus entry port (10). This is the core of the cellular mimesis function performed by the globule as shown in the sequences in Fig. 3.
In the first sequence of Fig. 3, the virus is close to a globule. The external protein hemagglutinin HA (8) of the viral pericapsid (9), common to all influenza airborne viruses, latches onto the sialic acid end of the ganglioside (7) contained in the cholesterol nanogranule of the lipid raft, thereby allowing local deformation of the globular layer and fusion of the phospholipid membrane (3) with the viral pericapsid (9).
The residue of the lipid fusion of the viral pericapsis with cholesterol and the globular phospholipid membrane (12) is shown in the second sequence of Fig. 3.
The subsequent access of the viral particle into the underlying cavity of the porous silica core (1) is depicted in the second progressive sequence of Fig. 3.
The virus encapsulated in the porous silica cavity (2) underlying the residue of the lipid raft (12) undergoes the aggression of the substances impregnated in the core as shown in the third sequence of Fig. 3.
After denaturation of the protein capsid (when it has dissolved) the specific compounds in the mixture can gain access to the viral nucleic acids (11), whether DNA or RNA, by intercalating between the bases of the ribose chain, fragmenting them, and rendering them inactive and unable to infect as shown (12) in the fourth sequence in Fig. 3.
The action of altering and breaking down nucleic acids can be greatly accelerated by the use of UV light, which triggers the formation of free radicals and peroxides through ammonium persulphate (NH^SzOsContained in the impregnation mixture. Particularly effective is the introduction of small amounts of carnosic acid C20H28O4 into the cholesterol granules. This performs a dual function by preserving cholesterol and linoleic acid from oxidation and above all promoting the fusion of the viral lipid membrane to that of the globule, thus mimicking the dynamics of viral penetration into the pulmonary alveoli. When an influenza virus penetrates lung tissue, haemagglutinin HA binds to the sialic acid of ganglioside receptors, and the alveoli respond with inflammation, acidifying the lungs. Paradoxically, acidification of the lungs favours virus penetration because haemagglutinin folds in an acidic environment and promotes the adhesion of the viral lipid pericapsid to the cell membrane. Thus, the more inflamed and acidic a lung is, the more a flu virus can infect it because lung acidity is effective only against bacterial pathogens and not viral ones. The insertion of carnosic acid into the cholesterol granule promotes lipid membrane fusion by exploiting the folding of viral haemagglutinin HA.
Each globule of porous silica, the subject of this discovery, has an extraordinary capacity for surface capture. This is due to the size (i.e. that of viruses with an average diameter more than 100 times smaller). It has been calculated that each porous silica globule has the potential to capture 30,000 viral particles with an average diameter of 100 nm because each viral particle engages a surface area of approximately 0.01 pm2 and a porous silica globule (10 pm in diameter) has a mantle area of over 300 pm2.
Considering that 1 ml of aqueous suspension can contain approximately one billion globules of porous silica, it can be deduced that a bottle with a volume of 100 ml can contain as many as one hundred billion globules of porous silica with a capture potential of 3 million billion viral particles.
In a highly pathogen-contaminated airborne environment, a concentration of up to 50 billion viral particles per cubic metre of air can occur. As a result, using a small volume of aqueous suspension, huge amounts of air can be purified for a long time before replacing the globular suspension, thus making this decontamination technology highly efficient and cost-effective.
The globular suspension is obtained in six sequential steps as shown in Fig. 4 and is based on the property of porous silica to absorb at temperatures around 60°C a quantity of liquid mixture of saturation approximately 25% higher than the quantity of saturation at room temperature of 20°C. During cooling, a part of the mixture is desorbed and fills the surface cavities of the porous silica because of the equilibrium of the pressure inside the globule with respect to the outside. This results in a pseudo- spherical conformation of the lipid mantle (3).
In the first phase (13) Fig. 4, the porous silica globules are impregnated at 60°C with the mixture (dissolving denaturing solution) for proteins and nucleic acids, thus bringing the globules to saturation.
In the second phase (14) Fig. 4, the first lipid mantle is created on the porous silica globules by introducing them into a mixture of phosphatidylcholine and phosphate- diethanolamine with the globules in excess of the lipids and maintaining the temperature at around 55°C so that the polar heads of the uniform phospholipids adhere around the globule until the porous surface cavities are partially filled.
The third step (15) (Fig. 4), consists in the preparation of the nanogranules of cholesterol and sialic acid gangliosides by inserting their homogeneous mixture in a dissolver with water until a size of about 200 nm is obtained.
In the fourth step (16) (Fig. 4), the nanogranules are mixed with the first layer of globular mantle so that they are evenly distributed on the mantle and are sufficiently spaced from each other. The nanogranules will preferentially be positioned within the cavities of the impregnated porous silica and partially filled by the phospholipids of the first phase because in these recesses, they are able to have more contact surface to form lipid bonds. The operation should be carried out at around 50°C so that the lipids remain fluid and more than 80% of the excess impregnation mixture is retained on the porous silica.
In the fifth phase (17) Fig. 4, the second lipid mantle formed by the phosphatidylcholine and phosphatidylserine is formed by inserting this into the globular suspension so that the mantle is uniformly coated at a temperature of 45°C. The phospholipids of the second layer will be arranged with the polar heads outwards and the lipid tails attached to the first mantle.
In the sixth and final preparatory step (18) (Fig. 4) the globules are cooled to ambient temperature (approx. 20°C) so that the porous silica globules release by desorption the excess mixture. This will fill the surface cavities, thereby pushing the first layer of phospholipids and the cholesterol nanogranules outwards.
Swellings form on the globular surface leaving the cholesterol nanogranules with their viral receptors partially uncovered (7). Lipid rafts form on the outside of the lipid bilayer, and cavities are filled with dissolving denaturing mixture in the area below; magnification of the illustration (2X) (Fig. 4).
The globules formed by this serial process are suitable for the capture and dissolution of suspended pathogens.
The intrinsic properties of this particular globular suspension allow for a high ratio between the volumetric flow rate of the air being treated and the mass of the globules in suspension. This achieves an exceptional compactness factor with the use of modest quantities of the viral dissolution preparation.
As an example, for a treatment plant with 500-1000 m3/h of air, a bottle of 100- 200 ml of globular suspension is sufficient to guarantee decontamination from viral pathogens for 8-10 weeks of continuous 24-hour sanitisation.
Thiazole orange C26H24N2O3S2 was also included in the impregnation mixture propriodine Iodide C27H34I2N4 and acts as a fluorescent dye when specifically intercalated with nucleic acids. Fluorescein isothiocyanate C21H11NO5S binds to the protein and phosphatidylserine portion of the outer mantle layer so that the globules
acquire a fluorescence intensity directly proportional to the viral load adsorbed and dissolved.
In particular, after viral adsorption the fluorescein isothiocyanate C21H11NO5S also penetrates the cholesterol nanogranule around the viral pericapside residues and attaches to the fostatidylserine present in this, thereby creating a fluorescent halo. Fluorescent dyes reveal when the dispersion needs to be replaced because the globules are coloured orange when exposed to sunlight and become extremely fluorescent when subjected to UV light.
By exploiting this fluorescent property, it is also possible to equip environmental sanitation systems, which use the globular suspension that is the subject of the present invention, with an automatic system in order to monitor the exhaustion of the capture capacity (subject of a separate patent application). Detection of the degree of saturation of the suspension enables the automatic filtering of the globules to be included so that the use of the equipment can be optimised according to the pathogen load present in the environment where it operates. A small percentage of ammonium persulphate (NH4)2S2O8 has also been added to the impregnation; the function of this is to peroxidise and polymerise the linolenic acid with the cholesterol present in the granule; this polymerisation occurs after virus capture and dissolution and is essential to prevent the cholesterol granule from being dissolved by the dimethyl sulfoxide C2H6OS present in the impregnation mixture and from crossing the phospholipid membrane and spilling outside the globular suspension. To catalyse the cleavage of ammonium persulphate (NH4)2S2O8, so as to accelerate the peroxidative polymerisation reaction, a small percentage of tetramethylethylenediamine (TEMED) C6H16N2 is added to the granule together with linoleic acid C18H32O2.
With the polymerisation of linolenic acid and cholesterol, a facsimile 'scarring' of the passageway that the virus opened during fusion and penetration into the globular phospholipid membrane takes place.
The suspension that causes the pathogenic structures to break down through the unique mechanism of cell mimesis does not result in the release of reaction products into the environment, even after prolonged operation.
Upon exhaustion, the suspension is collected in a special filtration capsule located within the environmental sanitation system, which collects the spent globules. Once removed from the environmental sanitation system, this capsule is not a special waste because the products it contains (i.e. aggregates of amino acids, lipids, and ribose residues) are biologically inactive. The solution of the aqueous suspension with the globules contained in the refill bottles is brought to saturation with a citric acid solution (40% by weight) in order to guarantee the preservation of the product and preserve the oxidation of the globules during operation in the environmental sanitisation system, thus resulting in an excellent anti-scale action if hard water is used for periodic refilling. Citric acid also acts as both an antibacterial agent and an acidifier of the environment outside the globules; this promotes viral capture and
fusion of globular lipid membranes with viral pericapsids.
Users of the specific environmental sanitisation systems, which employ this particular globular suspension technology covered by this invention, will not have any problems to deal with. The bottle containing the globular suspension and the filter cartridge need only be replaced periodically.
The industrial manufacture of this innovative and high-performance suspension, which uses commercially available materials, is cost effective and does not have a detrimental effect on operating costs. It can therefore be mass-produced to cover a very high diffusivity.
Claims
1) Porous silica globules impregnated with an aqueous mixture and covered with a mantle consisting of a phospholipid bilayer and placed in an aqueous suspension with the function of capturing and dissolving airborne viruses for application in environmental sanitation systems including:
(a) a covering mantle consisting of a first layer with the respective polar heads oriented towards the porous silica; composed of a mixture of (by weight) 60% phosphatidylcholine and 40% phosphate-diethanolamine and a second layer with the respective polar heads facing outwards. Inserted in these outward facing polar heads cholesterol nanogranules overlying the superficial porous cavities of the globule and equipped with viral receptors in contact with the aqueous suspension outside the globules, which is composed of a mixture of (by weight) 95% phosphatidylcholine and 5% phosphatidylserine b) nanogranules composed of 70% cholesterol, 18% linoleic acid C18H32O2, 10% sialic acid ganglioside GM1, 1.5% carnosic acid C20H28O4, and 0.5% tetramethylethylenediamine (TEMED) C6H16N2 inserted into the second layer consisting of a mixture of (by weight) 95% phosphatidylcholine and 5% phosphatidylserine c) An impregnation mixture consisting of (by weight) water H2O (40%), dimethyl sulphoxide C2H6OS (30%), guanidinium thiocyanate C2H6N4S (10%), guanidinium chloride CH6CIN3 (6%), urea CH4N2O (5%), sodium dodecyl sulphate C12H25NaSO4 (4%), ammonium persulphate (NH4)2S2O8 (3%), propridium iodide C27H34I2N4 (1.1%), Thiazole Orange C26H24N2O3S2 (0.6%), and fluorescein Isothiocyanate C21H11NO5S (0.3%).
(d) An aqueous mixture constituting the liquid suspension for storage and distribution of the globules, consisting of (by weight) 60% water H2O and 40% citric acid C6H8O7 .
2) Porous silica globules as per claim 1 with a of 1-100 pm
2.1) Porous silica globules as per claim 2 with a suggested diameter of 10 μm
3) Porous silica globules according to claim 1 characterised by porous surface cavities with a depth of 10-1000 nm.
3.1) Porous silica globules as per claim 3 of which the suggested depth is 100 nm.
4) Porous silica globules according to claim 1 wherein the mechanism of action of the globular suspension against airborne viruses takes place according to a sequential process of capture by sialic receptors (7) on cholesterol nanogranules (4), fusion of the lipid membrane (3) with the viral pericapsis (9), incorporation of the virus (10) into the surface cavity (2) of the porous silica (1), denaturation and dissolution of the virus protein capsid (10), intercalation of the nucleic acids, and disruption of the ribose sugar phosphate chains.
5) Porous silica globules according to claim 1 wherein the mechanism of action of interrupting the outward outflow of the imbibition mixture from the interstitium of
the lipid membrane (3) left by the englobed and dissolved virus according to claim 4 carried out by polymerisation activated by peroxidation of linolenic acid contained in the cholesterol nanogranule (4) by ammonium persulfate (NH4)2S2O8 contained in the impregnation mixture and catalysed by tetramethylethylenediamine (TEMED) C6H16N2 contained in the nanogranule (4).
6) Porous silica globules as per claim 1 wherein the mechanism of action of the fluorescence after viral incorporation performed by propridium iodide C27H34I2N4 together with thiazole orange C26H24N2O3S2 that intercalate with the nucleic acids in the cavity and do not cross the membrane (3) and fluorescein isothiocyanate C21H11 NO5S that permeates the membrane (3) during pericapsis fusion (9) binding to viral protein residues and to phosphatidylserine of the outer mantle layer (3).
7) Porous silica globules according to claim 1 wherein the obtaining of the globular suspension is carried out in 6 distinct serial steps:
• the impregnation (13) at 60°C of the porous silica globules (1) with the mixture of claim 1 paragraph d)
• the forming (14) of the first layer (5) of the mantle (3) at 55°C with the mixture of claim 1 paragraph c)
• the preparation (15) of the nanogranules of cholesterol (4) and sialic acid gangliosides (7) with the mixture of claim 1 paragraph 3 with dissolution in water until the size of 200 nm is obtained
• the insertion (16) of the cholesterol nanogranules (4) conducted at 50°C with the dissolution obtained from the previous third phase (15)
• the formation (17) of the second layer (6) of the coat (3) performed at 45°C with the mixture of claim 1 paragraph c) · the cooling (18) of the dissolution at 20°C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2102674.5 | 2021-02-25 | ||
| GB2102674.5A GB2604128B (en) | 2021-02-25 | 2021-02-25 | Aqueous solution of porous, phospholipid-coated silica globules impregnated with a denaturing mixture for inacvtivation of airborne viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022180448A1 true WO2022180448A1 (en) | 2022-09-01 |
Family
ID=75377495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2022/000048 WO2022180448A1 (en) | 2021-02-25 | 2022-03-08 | Porous silica globules impregnated by a denaturing mixture able to capture and dissolve airborne viruses |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2604128B (en) |
| WO (1) | WO2022180448A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029479A2 (en) * | 2001-08-10 | 2003-04-10 | Regents Of The University Of California | Sensitive and rapid detection of pathogenic organisms and toxins using fluorescent polymeric lipids |
| WO2013030831A2 (en) * | 2011-08-26 | 2013-03-07 | Vecoy Nanomedicines Ltd. | Pathogen and substance traps |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010048572A1 (en) * | 2008-10-23 | 2010-04-29 | Cornell University | A novel anti-viral method |
-
2021
- 2021-02-25 GB GB2102674.5A patent/GB2604128B/en active Active
-
2022
- 2022-03-08 WO PCT/IB2022/000048 patent/WO2022180448A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029479A2 (en) * | 2001-08-10 | 2003-04-10 | Regents Of The University Of California | Sensitive and rapid detection of pathogenic organisms and toxins using fluorescent polymeric lipids |
| WO2013030831A2 (en) * | 2011-08-26 | 2013-03-07 | Vecoy Nanomedicines Ltd. | Pathogen and substance traps |
Non-Patent Citations (2)
| Title |
|---|
| DANIEL A BRICARELLO ET AL: "Inhibiting hostpathogen interactions using membrane-based nanostructures", TRENDS IN BIOTECHNOLOGY, vol. 30, no. 6, 9 March 2012 (2012-03-09), pages 323 - 330, XP028507542, ISSN: 0167-7799, [retrieved on 20120309], DOI: 10.1016/J.TIBTECH.2012.03.002 * |
| SUN TAO ET AL: "Phospholipid-Coated Mesoporous Silica Nanoparticles Acting as Lubricating Drug Nanocarriers", POLYMERS, vol. 10, no. 5, 9 May 2018 (2018-05-09), pages 513, XP055923224, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415400/pdf/polymers-10-00513.pdf> DOI: 10.3390/polym10050513 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB202102674D0 (en) | 2021-04-14 |
| GB2604128A (en) | 2022-08-31 |
| GB2604128B (en) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shum et al. | Double emulsion templated monodisperse phospholipid vesicles | |
| ES2149613T5 (en) | PROCEDURE FOR THE PREPARATION OF MICROCAPSULES OF ACTIVE MATTERS COVERED BY A POLYMER AND NEW MICROCAPSULES OBTAINED IN PARTICULAR ACCORDING TO SUCH PROCEDURE. | |
| US20100213628A1 (en) | Methods and compositions for encapsulating active agents | |
| JP5575395B2 (en) | Method for producing an encapsulated product by sedimentation | |
| BRPI0611538A2 (en) | solid redispersible emulsion, process for producing and its use | |
| US20030175517A1 (en) | Production of polyelectrolyte capsules by surface precipitation | |
| Lucinda-Silva et al. | Microspheres of alginate-chitosan containing isoniazid | |
| JP7082358B2 (en) | How to make capsules made of a cross-linked hydrogel shell that surrounds the central core | |
| AR020210A1 (en) | COMBINATION OF TWO OR MORE ACTIVE INGREDIENTS IN MICROENCAPSULATED FORMULATIONS | |
| JP2002506719A (en) | Fabrication of nanocapsules and microcapsules by layered polyelectrolyte self-assembly | |
| US20140023688A1 (en) | Encapsulated oils | |
| WO2010108211A1 (en) | Triggered release | |
| WO2022180448A1 (en) | Porous silica globules impregnated by a denaturing mixture able to capture and dissolve airborne viruses | |
| Jiménez-Skrzypek et al. | Miniaturized green sample preparation approaches for pharmaceutical analysis | |
| CN104365595A (en) | Pesticide microcapsules produced by layer-by-layer self-assembly | |
| US20010008318A1 (en) | Artificial rock fragrance delivery system | |
| JPS59205985A (en) | Recovery of non-secretory substance produced from cell | |
| EP3100721B1 (en) | Capsule formulation | |
| Panisello et al. | Polysulfone/vanillin microcapsules production based on vapor-induced phase inversion precipitation | |
| Kulak et al. | Single-step fabrication of drug-encapsulated inorganic microspheres with complex form by sonication-induced nanoparticle assembly | |
| Yang et al. | Preparation of DNA-encapsulated polyethersulfone hollow microspheres for organic compounds and heavy metal ions removal | |
| CN114503984A (en) | Nanoscale antibacterial mosquito-repellent microcapsule and preparation method thereof | |
| CN104955560B (en) | Encapsulation system | |
| JP4272372B2 (en) | Microcapsule and manufacturing method thereof | |
| JP2007534466A (en) | Microcapsules with controllable or delayed release for immobilizing chemical and / or biological materials and methods for their production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22713022 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020237032911 Country of ref document: KR Ref document number: 202392418 Country of ref document: EA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22713022 Country of ref document: EP Kind code of ref document: A1 |